SynthesisFrontiers in psychiatry2025
Effectiveness of music therapy for children with autism spectrum disorder: meta-analysis and potential biological mechanisms.
Synthesis in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder characterized by deficits in social interaction, communication skills, and repetitive behaviors. However, no effective pharmacological treatments targeting core symptoms have yet been developed. As a non-pharmacological intervention, music therapy (MT) is increasingly being explored for its potential value in improving functional outcomes for children with autism. This study aims to examine the efficacy of MT for children with ASD through a meta-analysis. Method: We conducted a systematic review following the PRISMA guidelines. A comprehensive and systematic search of PubMed, Web of Science, and the Cochrane Library databases up to August 2025 was performed to identify studies on MT treatment for children with ASD. Continuous variables were reported as standardized mean differences (SMD) with 95% confidence intervals (CI). All analyses were conducted using Stata statistical software version 17.0. Results: Our meta-analysis included 18 studies. Results showed that MT significantly reduced the total score on the Autism Behavior Checklist (ABC) (SMD = -0.76, 95% CI: -1.31 to -0.22, P = 0.01) and Childhood Autism Rating Scale (CARS) total scores (SMD = -0.43, 95% CI: -0.73 to -0.14, P < 0.01). Specifically, compared with the control group, MT significantly improved social skills (SMD = -0.26, 95% CI: -0.46 to -0.05, P = 0.01), behavioral abilities (SMD = -0.72, 95% CI: -1.06 to -0.39, P < 0.01), and sensory (SMD = -0.87, 95% CI: -1.68 to -0.07, P = 0.03), emotional (SMD = -1.31, 95% CI: -1.98 to -0.64, P < 0.01), and verbal functioning (SMD = -0.65, 95% CI: -0.19 to 1.12, P = 0.01). Conclusion: In summary, MT demonstrates efficacy in improving behavioral symptoms associated with autism spectrum disorders. However, caution should be exercised when interpreting results due to limited research literature in some analyses. Further studies are needed to validate its therapeutic effects. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251252228.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.